The impact of highly effective modulator therapy on sinusitis and dysosmia in young children with cystic fibrosis: a prospective study protocol.
Christine M Liu, Jakob L Fischer, Edith T Zemanick...
https://pubmed.ncbi.nlm.nih.gov/39811548/Actively Recruiting
Led by University of California, Los Angeles · Updated on 2026-09-10
80
Participants Needed
6
Research Sites
N/A
Total Duration
Researchers are investigating how highly effective cystic fibrosis transmembrane conductance regulator CFTR modulators affect chronic rhinosinusitis CRS and problems with the sense of smell olfactory dysfunction in young children with cystic fibrosis. This observational study focuses on children aged 2 to 8 years old and compares those receiving these modulator therapies with those not receiving them. The goal is to understand if early treatment with these drugs can improve sinus and smell function in this group. The study includes two groups one group of children starting treatment with ivacaftor or elexacaftortezacaftorivacaftor known as highly effective modulator therapy or HEMT, and a control group not receiving HEMT. Participants in the HEMT group have assessments before starting therapy and at 1 and 2 years afterward. The control group undergoes the same assessments at similar intervals to track natural disease progression without treatment. Participants will undergo sinus MRI scans to measure sinus opacification and olfactory bulb volume, along with smell tests and quality of life surveys at baseline, 1 year, and 2 years. The study tracks changes in these outcomes over the two-year period. This includes specific smell tests like the Pediatric Smell Wheel and questionnaires assessing nasal symptoms and overall quality of life. The research team also monitors safety by recording any prior medication use or surgeries that may affect the results.
CONDITIONS
Sinus Disease in Young Children With Cystic Fibrosis
D
Daniel M Beswick, MD
M
Marlene Florian
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, Los Angeles
Lead Sponsor
University of Kansas Medical Center
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 years
Participants undergo baseline assessments including sinus MRI scans, smell tests, and quality of life surveys. Follow-up assessments occur at 1 year and 2 years to observe changes over time with or without treatment.
3 visits (baseline, 1 year, 2 years)
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Christine M Liu, Jakob L Fischer, Edith T Zemanick...
https://pubmed.ncbi.nlm.nih.gov/39811548/University of California, Los Angeles
Lead Sponsor
University of Kansas Medical Center
Collaborating Sponsor